List of Excipients in Branded Drug ZYVOX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pharmacia & Upjohn Company LLC	ZYVOX	linezolid	0009-4992	ANHYDROUS CITRIC ACID
Pharmacia & Upjohn Company LLC	ZYVOX	linezolid	0009-4992	DEXTROSE MONOHYDRATE
Pharmacia & Upjohn Company LLC	ZYVOX	linezolid	0009-4992	HYDROCHLORIC ACID
Pharmacia & Upjohn Company LLC	ZYVOX	linezolid	0009-4992	SODIUM HYDROXIDE

Zyvox Excipient Strategy and Commercial Opportunities for Linezolid

Last updated: August 4, 2026

Zyvox, Pfizer’s linezolid product, has limited originator exclusivity and broad generic competition. The commercial opportunity is concentrated in excipient optimization, pediatric acceptability, ready-to-use liquid dosage forms, IV supply reliability, and differentiated packaging rather than in basic immediate-release tablets. The strongest opportunities are formulations that improve taste, suspension stability, dose flexibility, storage, or hospital workflow without changing linezolid exposure.

What is Zyvox and which dosage forms contain linezolid?

Zyvox contains linezolid, a synthetic oxazolidinone antibacterial used for susceptible Gram-positive infections, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. FDA-approved dosage forms include tablets, oral suspension, and intravenous injection [1].

Zyvox dosage form	Strength or concentration	Principal commercial use
Film-coated tablets	600 mg	Adult and adolescent outpatient treatment
Oral suspension	100 mg/5 mL after reconstitution	Pediatric and swallowing-limited patients
Intravenous injection	2 mg/mL	Hospitalized patients requiring parenteral therapy
Generic equivalents	Comparable strengths and routes	Price-driven hospital and retail markets

Linezolid has high oral bioavailability, approximately 100%, allowing conversion from IV to oral therapy without a dose change in appropriate patients [1]. That pharmacokinetic characteristic reduces the clinical need for complex oral delivery technologies, but it increases the value of convenient and well-tolerated oral formulations.

What excipients are used in Zyvox tablets?

Zyvox tablets use conventional excipients for direct compression or related solid-dose manufacturing functions. The excipient system supports tablet strength, disintegration, coating performance, lubrication, and visual identification.

Representative tablet excipients listed in U.S. product labeling include microcrystalline cellulose, hydroxypropyl cellulose, sodium starch glycolate, magnesium stearate, hypromellose, polyethylene glycol, titanium dioxide, and colorants [1,2].

Excipient class	Typical Zyvox tablet function	Commercial relevance
Microcrystalline cellulose	Diluent and compression aid	Widely available; low differentiation
Hydroxypropyl cellulose	Binder	Supports tablet integrity
Sodium starch glycolate	Superdisintegrant	Helps rapid tablet breakup
Magnesium stearate	Lubricant	Requires control of blending and over-lubrication
Hypromellose	Film-coating polymer	Enables coating uniformity and protection
Polyethylene glycol	Coating plasticizer	Supports flexible film formation
Titanium dioxide and colorants	Opacity and product identification	Useful for brand differentiation and serialization

Which tablet excipients create the greatest development opportunity?

The greatest opportunity is not replacement of every incumbent excipient. It is targeted optimization of the manufacturing process and patient-use profile.

Generic manufacturers can pursue:

1. Direct-compression formulations with lower compression force and faster disintegration.
2. Low-dust excipient systems that reduce containment and cleaning costs.
3. Colorant-free or titanium-dioxide-free coatings for markets with changing excipient preferences.
4. Film coatings with improved moisture protection.
5. Smaller tablets or orally disintegrating formats for patients with dysphagia.
6. Co-processsed fillers and binders that reduce tablet weight and tooling requirements.

A tablet formulation that is materially easier to manufacture can support margin improvement even when the active ingredient is commoditized. The regulatory burden remains lower when the formulation stays within an immediate-release, systemically equivalent profile.

What excipients are used in Zyvox oral suspension?

Zyvox oral suspension is reconstituted to 100 mg/5 mL. The formulation uses a dry powder system that must remain physically stable during storage, disperse rapidly after reconstitution, deliver a uniform dose, and maintain acceptable taste.

The labeled excipient profile includes sucrose, mannitol, aspartame, sodium citrate, sodium chloride, xanthan gum, colloidal silicon dioxide, and sodium benzoate, with flavoring components identified in the product information [1,2].

Formulation requirement	Relevant excipient strategy
Sweetness	Sucrose, mannitol, high-intensity sweeteners
Taste masking	Flavor systems, polymeric barriers, ion-complexation approaches
Suspension viscosity	Xanthan gum or alternative suspending polymers
Redispersibility	Controlled particle size and optimized rheology
Chemical stability	Citrate buffering and moisture-control packaging
Microbial protection	Sodium benzoate or other permitted preservatives
Powder flow	Colloidal silicon dioxide and granulation control
Pediatric acceptance	Flavor selection, low grittiness, low aftertaste

How can manufacturers improve linezolid oral suspension?

Pediatric oral suspension is the most defensible excipient-led opportunity in the Zyvox franchise. Development priorities include:

• Improved taste masking without excessive viscosity.
• Lower sucrose content for patients requiring glycemic control.
• Alternative sweetener systems for patients with dietary restrictions.
• Better redispersibility after prolonged storage.
• Smaller reconstitution volume and easier dose measurement.
• Unit-dose sachets or premeasured bottles.
• Longer in-use stability after reconstitution.
• Reduced sedimentation and lower dosing variability.

A formulation that uses a novel taste-masking matrix, coated linezolid particles, or a spray-dried powder could create product differentiation. The commercial value depends on whether the product can demonstrate acceptable bioequivalence, stability, preservative effectiveness, and pediatric usability.

Taste masking must be designed around linezolid’s sensory profile rather than treated as a conventional flavoring exercise. Sweeteners can suppress bitterness but may not adequately control lingering aftertaste. Polymer coating, lipid-based barriers, ion-exchange systems, and multiparticulate approaches can provide stronger masking, although each introduces manufacturing and dissolution risks.

What excipients are used in Zyvox injection?

Zyvox injection is supplied as a ready-to-use 2 mg/mL solution in a 5% dextrose vehicle. The formulation includes sodium citrate, citric acid, and pH-adjusting agents as applicable to the labeled product [1].

The commercial formulation priorities are different from those for tablets and suspension:

• Chemical stability during shelf life.
• Container compatibility.
• Low particulate burden.
• Control of pH and osmolality.
• Resistance to precipitation or discoloration.
• Reliable terminal sterilization or aseptic processing.
• Compatibility with hospital administration systems.

What IV formulation opportunities exist for generic linezolid?

The ready-to-use IV market has a lower formulation barrier than injectable products requiring reconstitution, but it has higher operational and quality requirements. Opportunities include:

• Flexible bags with improved port design.
• Smaller-volume presentations for fluid-restricted patients.
• Premixed products optimized for hospital pharmacy workflow.
• Reduced overfill and lower packaging waste.
• Improved oxygen and moisture barrier systems.
• More robust compatibility with automated infusion devices.
• Alternative container materials with lower extractables and leachables risk.

The primary commercial advantage is often supply reliability rather than clinical differentiation. Hospitals may value a second source, dependable allocation, and packaging that reduces preparation steps.

When did Zyvox lose exclusivity?

Zyvox’s principal U.S. composition-of-matter patent protection expired in the mid-2010s. FDA approved Zyvox in 2000, and the product received five years of new chemical entity exclusivity plus pediatric exclusivity associated with its approved development program [1,3].

Milestone	Approximate timing
FDA approval of Zyvox	April 2000
New chemical entity exclusivity	Expired in 2005
Principal linezolid patent protection	Expired in the mid-2010s
Generic linezolid competition	Established after patent expiry
Current market position	Mature generic market

Exact patent term calculations can vary because of patent-term adjustment, patent-term extension, pediatric exclusivity, and the specific patent claim at issue. The commercial conclusion is clear: linezolid is no longer protected by a meaningful originator exclusivity barrier in the United States.

What is the Orange Book status of Zyvox?

The FDA Orange Book historically listed Zyvox-related patents and exclusivity information, but current generic entry is not materially constrained by an active composition-of-matter barrier. Generic linezolid products are approved in tablet, oral suspension, and injection forms through abbreviated new drug applications.

Relevant regulatory issues include:

• Paragraph IV certifications against any listed patents.
• Paragraph III certifications where a listed patent remains enforceable but has a future expiry date.
• Labeling carve-outs for patented methods of use.
• Bioequivalence requirements that differ by dosage form.
• Drug master file and manufacturing-site obligations for excipients and active pharmaceutical ingredient suppliers.

Because linezolid is a small-molecule product, biosimilar regulation does not apply. Generic applicants use the ANDA pathway rather than the 351(k) biosimilar pathway [3,4].

Which companies are challenging or competing with Zyvox?

Competition comes from multiple generic manufacturers, including large global suppliers and specialty injectable manufacturers. Market participation can vary by dosage form and supply contract.

Competitive group	Main advantage
Large generic companies	Scale, broad distribution, lower unit cost
Hospital injectable suppliers	Formulary relationships and IV manufacturing
Retail generic suppliers	Pharmacy access and tablet volume
Specialty pediatric companies	Taste-masked and flexible liquid products
Contract manufacturers	Lower-cost production and regional supply
Originator or authorized-generic channels	Brand recognition and procurement continuity

The most attractive competitive niche is not a standard 600 mg tablet. It is a differentiated liquid, pediatric product, ready-to-administer IV presentation, or supply-secure hospital product.

What formulation patents could protect a new linezolid product?

A new linezolid product could be protected by patents directed to:

• Taste-masked linezolid particles.
• Specific polymer coatings or multiparticulate systems.
• Stable dry-powder suspensions.
• Low-sucrose or sugar-free oral liquids.
• Improved redispersibility.
• Extended in-use stability.
• Specific IV container and closure systems.
• Manufacturing processes that control particle size or polymorphic form.
• Combination products or administration kits.
• Narrow method-of-use claims tied to dosing or patient populations.

How strong would a new linezolid formulation patent be?

Patent strength would depend on technical specificity and the distance from conventional excipient substitution.

Claim type	Relative strength
Broad use of a known sweetener	Weak
Routine substitution of one suspending agent	Weak to moderate
Defined particle coating with demonstrated taste masking	Moderate to strong
Formulation with unexpected stability or dissolution result	Stronger
Packaging claim tied to measurable stability improvement	Moderate
Manufacturing process with critical parameters	Moderate
Broad “linezolid plus excipient” claim	Vulnerable to obviousness attacks

The strongest filing strategy would pair composition claims with process, stability, and use claims. Comparative data should show an unexpected result, such as superior taste scores, reduced sedimentation, longer in-use stability, or improved dissolution after storage.

What generic entry risks exist for a new Zyvox formulation?

A new product faces three principal risks.

First, the active ingredient is mature and widely available. This limits pricing power and makes conventional formulations vulnerable to rapid generic substitution.

Second, formulation patents may be challenged under obviousness, anticipation, lack of written description, or enablement theories. Claims based only on routine excipient selection are particularly exposed.

Third, the commercial market may not reward incremental convenience unless the product reduces total treatment cost, improves adherence, or solves a hospital procurement problem.

A differentiated oral suspension has better protection prospects than a conventional tablet, but it also requires stronger evidence. FDA review will focus on pharmaceutical equivalence, bioequivalence, microbiological quality, stability, preservative performance, and labeling.

How do Zyvox excipient opportunities compare with other antibiotics?

Product category	Excipient-led opportunity	Commercial barrier
Linezolid tablets	Moderate	Heavy generic price competition
Linezolid oral suspension	High	Taste, stability, pediatric evidence
Linezolid injection	Moderate	Sterility, packaging, hospital contracts
Vancomycin injection	Lower for standard products	Established hospital supply base
Pediatric beta-lactam suspensions	High	Crowded market and frequent substitutions
Long-acting antibiotic formulations	High	Complex development and clinical requirements

Linezolid has a distinct advantage over many antibiotics because oral bioavailability supports IV-to-oral conversion. A manufacturer that combines a reliable IV product with an acceptable oral liquid can pursue hospital formulary and discharge-prescription opportunities.

What licensing deals could support a linezolid excipient strategy?

Potential licensing targets include:

• Taste-masking platforms.
• Spray-drying or fluid-bed coating technologies.
• Pediatric flavor systems.
• High-solids suspension platforms.
• Ready-to-use IV bag technologies.
• Preservative systems with extended in-use stability.
• Co-processed excipient systems.
• Regional commercialization rights for hospital products.

A license is commercially justified when it shortens development time or creates claimable technical differentiation. Licensing a generic flavor system without exclusivity or measurable performance advantages is unlikely to support durable margins.

What is the revenue exposure of the Zyvox market?

Pfizer does not generally report Zyvox revenue as a separately detailed current growth franchise in its public financial reporting. The originator opportunity is therefore limited relative to its historical peak, while generic volume remains relevant in hospital and outpatient antibacterial procurement.

Revenue exposure is strongest in:

1. High-volume hospital contracts for IV linezolid.
2. Retail and specialty pharmacy tablet supply.
3. Pediatric and swallowing-limited patient segments.
4. Regions with limited generic competition.
5. Markets where reliable supply commands a procurement premium.

The main investment thesis is operational. A low-cost, high-quality excipient and manufacturing platform can support margin through yield, throughput, stability, and reduced quality failures rather than through premium pricing for the active ingredient.

What is the best commercial excipient strategy for Zyvox?

The strongest strategy is a portfolio approach:

Adult tablet

Use a conventional, low-cost immediate-release formulation with robust compression, fast disintegration, and a moisture-controlled coating. Avoid unnecessary excipient complexity.

Pediatric oral suspension

Prioritize taste masking, low sedimentation, accurate dosing, and patient-friendly packaging. Consider a sugar-reduced or sugar-free variant only if palatability and stability remain competitive.

Hospital injection

Focus on ready-to-use packaging, dependable supply, container compatibility, low particulate risk, and reduced pharmacy handling.

Intellectual property

File coordinated patents covering the formulation, manufacturing process, packaging, and measurable stability or taste benefits. Avoid reliance on broad claims covering routine excipient substitutions.

Commercial execution

Target hospital formularies, pediatric specialists, specialty pharmacies, and regional markets where generic supply is inconsistent. A differentiated liquid or IV product offers a better return profile than another standard linezolid tablet.

Key Takeaways

• Zyvox contains linezolid and is available as tablets, oral suspension, and IV injection.
• The principal linezolid exclusivity barriers expired years ago, and generic competition is established.
• Tablet excipients are largely conventional and offer limited standalone differentiation.
• Oral suspension is the strongest excipient-led opportunity because taste, redispersibility, stability, and dosing convenience affect uptake.
• IV commercial value depends on packaging, supply reliability, and hospital workflow.
• Biosimilar risk does not apply because linezolid is a small molecule.
• New formulation patents are strongest when supported by unexpected taste, stability, dissolution, or manufacturing results.
• The most attractive commercial product is a differentiated pediatric liquid or hospital-ready IV presentation, not a conventional 600 mg tablet.

FAQs

Can linezolid be formulated as a sugar-free oral suspension?

Yes. A sugar-free linezolid suspension could use polyols, high-intensity sweeteners, suspending polymers, and a taste-masking system. The main development challenges are aftertaste, viscosity, preservative performance, and stability after reconstitution.

Does linezolid require a new clinical trial for every excipient change?

Not necessarily. The regulatory pathway depends on the extent of the formulation change, dosage form, product performance, and applicable FDA requirements. Demonstration of pharmaceutical equivalence, bioequivalence, stability, and product quality may support an ANDA or supplemental pathway without a full efficacy trial.

Is Zyvox oral suspension more commercially defensible than Zyvox tablets?

Usually. Oral suspension has more formulation variables and patient-use attributes that can support differentiation. Tablets are easier to manufacture and substitute, which increases price competition.

Can a new linezolid formulation receive pediatric exclusivity?

A new formulation does not automatically receive pediatric exclusivity. Pediatric exclusivity is generally linked to completion of FDA-requested pediatric studies under the applicable statutory framework, not merely to developing a child-friendly excipient system.

Can excipient suppliers capture value without owning a linezolid product?

Yes. Suppliers can commercialize co-processed excipients, taste-masking platforms, coating systems, suspension technologies, or IV packaging components through licensing, supply agreements, or contract development partnerships. The strongest value proposition is a demonstrable improvement in manufacturability, stability, dosing accuracy, or patient acceptability.

References

1. U.S. Food and Drug Administration. (2000). Zyvox (linezolid) prescribing information. FDA.

2. DailyMed. (n.d.). Zyvox: Linezolid tablet, granule, and injection labeling. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. FDA.